c14950.htm - Prepared by Imprima

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

May 31, 2011

________________

 

        NOVO NORDISK A/S       
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

Company Announcement

30 May 2011

Novo Nordisk A/S – Share repurchase programme

 

On 28 April 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

 

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 28 April 2011 to 2 August 2011.

 

Since the announcement as of 23 May 2011, the following transactions have been made under the programme:

 

Number of

Average

Transaction value,

 

shares

purchase price

DKK

Accumulated, last

announcement

857,000

 

550,235,947

23 May 2011

45,000

647.4800

29,136,600

24 May 2011

45,000

648.9720

29,203,740

25 May 2011

45,000

653.2600

29,396,700

26 May 2011

50,000

647.9800

32,399,000

27 May 2011

45,000

648.1800

29,168,100

Accumulated under

the programme

1,087,000

 

699,540,087

 

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 2,275 B shares in the period from 23 May 2011 to 27 May 2011. The shares in these transactions were not part of the Safe Harbour repurchase programme.

 

Company Announcement no 33 / 2011

Page 1 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

 

With the transactions stated above, Novo Nordisk owns a total of 11,312,814 treasury shares, corresponding to 2.0% of the share capital. The total amount of shares in the company is 580,000,000 including treasury shares.

 

Novo Nordisk expects to repurchase B shares worth DKK 10.0 billion during 2011. As of 27 May 2011, Novo Nordisk has repurchased a total of 4,140,338 B shares equal to a transaction value of DKK 2,699,539,888.

 

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

 

Further information:

 

 

 

Media:

Investors:

 

 

Outside North America:

Anne Margrethe Hauge

Tel: (+45) 4442 3450

amhg@novonordisk.com

 

Klaus Bülow Davidsen

Tel: (+45) 4442 3176

klda@novonordisk.com

 

 

 

Jannick Lindegaard

Tel: (+45) 4442 4765

jlis@novonordisk.com

 

 

In North America:

 

Ken Inchausti

Tel: (+1) 609 514 8316

kiau@novonordisk.com

Frank Daniel Mersebach

Tel: (+45) 4442 0604

fdni@novonordisk.com

 

 

 

Company Announcement no 33 / 2011

Page 2 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: May 31, 2011

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer